AGIO 8-K: SEC filing
Agios Pharmaceuticals
Filed with the SEC on · accession 0001439222-26-000129
AGIO filed a 8-K (current report) with the SEC on Nov 5, 2026. Agios Pharmaceuticals reported record third-quarter 2026 net product revenue of $55.4 million, driven by the U.S. launch of AQVESME in thalassemia, and announced the FDA extended the PDUFA goal date for its mitapivat sickle cell disease sNDA by three months to February 1, 2027. The stock moved -9.9% by the first close after the filing.
Summary of the filing
Agios Pharmaceuticals reported record third-quarter 2026 net product revenue of $55.4 million, driven by the U.S. launch of AQVESME in thalassemia, and announced the FDA extended the PDUFA goal date for its mitapivat sickle cell disease sNDA by three months to February 1, 2027. The company also disclosed R&D headcount reductions of over 100 roles and ended the quarter with $907.0 million in cash.
Key details
How AGIO stock reacted
Close before
$31.38
Nov 4, 2026
First close after
-9.91%
$28.27
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for AGIO, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for AGIO?
Click hereFrequently asked questions
What did AGIO file with the SEC on Nov 5, 2026?
AGIO filed a 8-K (SEC filing). Agios Pharmaceuticals reported record third-quarter 2026 net product revenue of $55.4 million, driven by the U.S. launch of AQVESME in thalassemia, and announced the FDA extended the PDUFA goal date for its mitapivat sickle cell disease sNDA by three months to February 1, 2027. The company also disclosed R&D headcount reductions of over 100 roles and ended the quarter with $907.0 million in cash.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
How did AGIO stock react to this filing?
AGIO closed at $31.38 before the filing and $28.27 on Nov 5, 2026 (-9.91%).
Other AGIO SEC filings
Get alerts when AGIO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days